glp 1 nejm publishes Phase 3 trial results for orforglipron, an oral GLP-1 obesity medication. | Scott Isaacs, MD, FACP, FACE posted on the topic @nejm correct today’s review of

15 Alzheimers Disease GLP1 receptor agonists are under investigation for their potential impact on neurodegenerative diseases, such as Alzheimers disease

Provider practice habits and barriers to care in obesity management in a large multicenter health system

1 Pharmacological GLP-1 receptor agonists (GLP-1RAs) have been developed that mimic the physiological effects of GLP-1 to manage type 2 diabetes and obesity

This is potentially completed by reducing oxidative damage to tissues in your heart, which can reduce the likelihood of heart disease, strokes, heart attacks and other serious conditions

Health benefits begin almost as soon as you stop